Technical Analysis for GOVX - GeoVax Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Buy Setup | Bullish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Parabolic Rise | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
200 DMA Resistance | Bearish | 2.98% | |
Jack-in-the-Box Bullish | Bullish Swing Setup | 2.98% | |
Volume Surge | Other | 2.98% |
Alert | Time |
---|---|
Rose Above Upper Bollinger Band | about 9 hours ago |
2x Volume Pace | about 9 hours ago |
1.5x Volume Pace | about 9 hours ago |
3x Volume Pace | about 9 hours ago |
Up 5% | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 08/07/2024
GeoVax Labs, Inc. Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapies Vaccines Allergy Hepatitis B Department Of Defense Viruses HIV Immunodeficiency U.S. Department Of Defense Virus Malaria Virology Fever Ebola Zika Chronic Hepatitis Scripps Vaccinia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.2405 |
52 Week Low | 1.0901 |
Average Volume | 3,379,247 |
200-Day Moving Average | 4.21 |
50-Day Moving Average | 1.78 |
20-Day Moving Average | 2.02 |
10-Day Moving Average | 2.45 |
Average True Range | 0.65 |
RSI (14) | 64.66 |
ADX | 38.53 |
+DI | 40.53 |
-DI | 8.05 |
Chandelier Exit (Long, 3 ATRs) | 2.96 |
Chandelier Exit (Short, 3 ATRs) | 3.03 |
Upper Bollinger Bands | 3.40 |
Lower Bollinger Band | 0.64 |
Percent B (%b) | 0.96 |
BandWidth | 136.55 |
MACD Line | 0.37 |
MACD Signal Line | 0.19 |
MACD Histogram | 0.1808 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.30 | ||||
Resistance 3 (R3) | 4.36 | 4.08 | 4.13 | ||
Resistance 2 (R2) | 4.08 | 3.82 | 4.05 | 4.07 | |
Resistance 1 (R1) | 3.68 | 3.66 | 3.88 | 3.62 | 4.02 |
Pivot Point | 3.40 | 3.40 | 3.50 | 3.37 | 3.40 |
Support 1 (S1) | 3.00 | 3.14 | 3.20 | 2.94 | 2.54 |
Support 2 (S2) | 2.72 | 2.98 | 2.69 | 2.49 | |
Support 3 (S3) | 2.32 | 2.72 | 2.43 | ||
Support 4 (S4) | 2.26 |